F8 and hemophilia A: All the hemophilia A mice treated with LV.coFVIII or coFVIII.XTEN showed improved hemostasis, comparable to the range observed for wt mice, while hemostasis remained defective in mice treated with LV.FVIII that only expressed approximately 20% of normal FVIII on average (Fig. 1d).